142 related articles for article (PubMed ID: 37380459)
21. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
[TBL] [Abstract][Full Text] [Related]
22. [A Case of Malignant Peritoneal Mesothelioma Treated with Cisplatin and Pemetrexed].
Sone T; Omori S; Hayashi K; Yamato H; Ohira K; Kondo N; Takagi Y; Kato K
Gan To Kagaku Ryoho; 2018 Jun; 45(6):993-995. PubMed ID: 30026430
[TBL] [Abstract][Full Text] [Related]
23. Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma.
Rizzolo A; Ah-Lan KC; Nu TNT; Alcindor T
Clin Colorectal Cancer; 2022 Dec; 21(4):371-374. PubMed ID: 36055919
[No Abstract] [Full Text] [Related]
24. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
Parikh K; Hendriks LEL; Bironzo P; Remon J
Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG Uptake of Localized Malignant Peritoneal Mesothelioma.
Kodama E; Kodama T; Ichikawa T; Ikoma H; Hashimoto J
Clin Nucl Med; 2020 Feb; 45(2):161-163. PubMed ID: 31876833
[TBL] [Abstract][Full Text] [Related]
26. [A case of diffuse peritoneal malignant mesothelioma--intraabdominal administration of cisplatin is useful for diminishing ascites].
Noguchi T; Kawamura M; Kawamura T; Shimamura T; Sasaki K; Hosono T; Sato R; Murakami K
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1975-8. PubMed ID: 20948267
[TBL] [Abstract][Full Text] [Related]
27. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.
Yoneda H; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Ogino H; Otsuka K; Nishioka Y
BMC Pulm Med; 2021 Nov; 21(1):373. PubMed ID: 34781910
[TBL] [Abstract][Full Text] [Related]
28. Peritoneal malignant mesothelioma: Slippery like an eel to diagnose on cytology-case series of 3 cases.
Gupta N; Soni A; Mahajan R; Selhi P; Tyagi R; Garg B; Kaur H
J Am Soc Cytopathol; 2022; 11(1):40-45. PubMed ID: 34602383
[TBL] [Abstract][Full Text] [Related]
29. CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis.
Yin WJ; Zheng GQ; Chen YF; Chen DQ; Sun NN; Yang YX; Sun XY; Kang LQ
Radiol Med; 2016 Apr; 121(4):253-60. PubMed ID: 26661955
[TBL] [Abstract][Full Text] [Related]
30. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy.
Foote MB; Shia J; Zauderer MG; Nash GM; Cercek A
J Immunother; 2022 Feb-Mar 01; 45(2):100-103. PubMed ID: 34723916
[TBL] [Abstract][Full Text] [Related]
32. Primary malignant peritoneal mesothelioma mimicking tuberculous peritonitis: A case report.
Lin LC; Kuan WY; Shiu BH; Wang YT; Chao WR; Wang CC
World J Clin Cases; 2022 Apr; 10(10):3156-3163. PubMed ID: 35647134
[TBL] [Abstract][Full Text] [Related]
33. Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge.
Marques de Sousa S; Pereira F; Duarte M; Marques M; Vázquez D; Marques C
GE Port J Gastroenterol; 2020 Apr; 27(3):197-202. PubMed ID: 32509926
[TBL] [Abstract][Full Text] [Related]
34. Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade.
Saisho C; Ishii H; Edakuni N; Imamura Y; Tokito T; Kinoshita T; Azuma K; Yamada K; Hoshino T
Intern Med; 2016; 55(21):3161-3164. PubMed ID: 27803412
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA; Ewings S; Ottensmeier C; Califano R; Hanna GG; Hill K; Danson S; Steele N; Nye M; Johnson L; Lord J; Middleton C; Szlosarek P; Chan S; Gaba A; Darlison L; Wells-Jordan P; Richards C; Poile C; Lester JF; Griffiths G;
Lancet Oncol; 2021 Nov; 22(11):1530-1540. PubMed ID: 34656227
[TBL] [Abstract][Full Text] [Related]
36. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
37. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
38. [A case of malignant peritoneal mesothelioma diagnosed with laparoscopic biopsy].
Yagi Y; Maeda T; Yoshimitsu Y; Sakuma H
Gan To Kagaku Ryoho; 2014 Aug; 41(8):995-7. PubMed ID: 25132032
[TBL] [Abstract][Full Text] [Related]
39. Primary pericardial mesothelioma complicated by pericardial calcification.
Zhang J; Liu D; Zhang D; Guo K; Yang X
BMC Cardiovasc Disord; 2023 Mar; 23(1):125. PubMed ID: 36890475
[TBL] [Abstract][Full Text] [Related]
40. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
